Company Summary:

FL87, Inc. is a privately held, early-stage biotechnology company developing a novel DNA platform that can address currently untreatable diseases.

FL87 was founded by Flagship Pioneering, an innovation enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 100 groundbreaking companies over the past twenty years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Moderna (MRNA), Syros Pharmaceuticals (SYRS), Seres Therapeutics (NASDAQ: MCRB), Generate Biomedicines, Tessera Tx, Evelo Biosciences (EVLO), and Indigo Agriculture.

Position Summary:

FL87 is seeking and Scientist, Immunology that will lead our efforts to develop and improve novel nucleic acid platforms in the field of vaccine development and immunotherapy. This is a highly visible role that is cross-functional with different research teams to drive in vitro, ex vivo and in vivo applications with our nucleic acid platform. We are searching for a driven, enthusiastic, and self-motivated individual who is comfortable multitasking and working independently on various aspects of the platform. This individual will join a dynamic, rapidly growing, and highly collaborative team.

Responsibilities:

• The successful candidate will work both independently and as part of a team to design, plan and execute high-quality biochemical, cell-based, and translational assays.
• Contribute to all different stages of the program from inception, in vitro optimization, in vivo studies, and lead identification of therapeutic payloads.
• Lead the development, optimization, and execution of assays to test important hypotheses.
• Collaborate with internal and external research teams and CROs to advance our translational programs.
• Critical data analysis, attention to detail, and ability to work effectively in fast-paced environments.
• Organize and present data in high level meetings.
• Mentor and train research associates as needed.

Qualifications:

• PhD. in Immunology, Oncology, Cell Biology, Molecular Biology, Biochemistry, Bioengineering or related discipline with > 1-3 years of experience in a biotech or pharmaceutical company (the title will be adjusted for the level of experience).
• Deep knowledge and understanding of immunology especially in the context of vaccination. Proficient in experimental design, assay execution, troubleshooting, data analysis, and data interpretation.
• Extensive hands-on experience in mammalian cell culture including immune cell and primary cells and in handling tissues.
• Experience in the research of immune-oncology and immune cell engineering (e.g., CAR-T, CAR-NK) is also preferred.
• The ideal candidate has previous experience in immunology therapies and structural biology, cell-based genetic manipulations (e.g., siRNA, ASO) and RNA/DNA delivery.
• Experience in the following techniques is a plus: FACS, RT-qPCR, RNA-seq, cloning, cell culture, IHC and quantitative image analysis, Meso Scale Discovery, high-content screening.
• Strong written and oral presentation skills.
• Execution focused, team oriented, and highly motivated.

Ideal Attributes:

• Deep domain experience in vaccine, T and B cell biology, and tumor microenvironment.
• Experience with both in vitro and in vivo nucleic acid delivery.
• Experience in leading projects and mentoring junior reports.

Location: Cambridge, MA

More About Flagship Pioneering

We are creative optimists and we would love for you to consider joining our team!  See all our open opportunities across Flagship Pioneering’s Ecosystem!

Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture.  Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies, and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies. Learn more about Flagship at www.flagshippioneering.com.

We believe pioneering is best done by teams, and that it is a process that can be taught, learned, and replicated.  Learn more about our Company Creation Model. Can Breakthrough Innovations Be Made Systematically? A Conversation With Noubar Afeyan, Flagship Pioneering’s CEO.

Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.

At Flagship, we recognize there is no perfect candidate. If you have some of the experience listed above but not all, please apply anyway. Experience comes in many forms, skills are transferable, and passion goes a long way. We are dedicated to building diverse and inclusive teams and look forward to learning more about your unique background.

Recruitment & Staffing Agencies:  Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates.  The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team.   Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.

#LI-SO1